RE: Research23 Apr 2020 16:33
Avacta has two main assets, firstly, Dr. Alastair Smith. Having met him a few times, I find him to be the kind of guy that you would follow to the ends of the earth, very bright, shrewd and full of enthusiasm, but still has time to talk to the small investor. Secondly, the Affimer platform. Both thrapeutics and diagnostics have enormous potential, and when Affimers are proven to be safe and effective after in vivo tests are completed, the improvement in cancer treatment will be transformational, as will the share price.